Lactobacillus gasseri shows promiseCharacterization of a Lactobacillus gasseri strain as a probiotic for female vaginitis.
We investigated the potential of a specific strain of Lactobacillus gasseri, named VHProbi E09, to treat vaginitis and fight off common pathogens causing yeast infections. Through laboratory tests, we found that this strain effectively inhibited the growth of harmful bacteria and yeast by over 99%.
Additionally, it prevented these pathogens from adhering to vaginal cells, showing promise for future clinical applications. While these results are promising, further research is necessary to fully understand its effectiveness in clinical settings and its role in restoring normal vaginal flora.
Read More
Lactobacillus rhamnosus shows promiseIdentification of sulfur components enhancing the anti-Candida effect of Lactobacillus rhamnosus Lcr35.
We investigated how Lactobacillus rhamnosus Lcr35, contained in the GYNOPHILUS product, can combat yeast infections like Candida. This study showed that the product’s formulation, enhanced by sodium thiosulfate, improves its ability to kill yeast cells.
Remarkably, after 48 hours of co-culturing, the yeast’s viability dropped to zero. The presence of odor-active sulfur compounds, specifically S-methyl thioacetate, was linked to this antifungal effect.
Interestingly, achieving the full antifungal impact relies on these sulfur components.
Read More
Novel yeast infection treatment studiedDual Mechanisms of Action: Anti-Candida and Anti-Inflammatory Potential of Fermentation Broth in Treating Vulvovaginal Candidiasis.
We examined a new treatment, VAGINNE, derived from beneficial species to tackle vulvovaginal candidiasis (VVC). Using a mouse model, we observed that VAGINNE improved the balance of the vaginal microbiome while reducing harmful yeast growth.
Additionally, it lowered inflammatory markers in both vaginal tissue and blood, suggesting an anti-inflammatory effect. Our histological analysis showed better tissue integrity in treated mice compared to those without treatment.
These results indicate that VAGINNE can be a promising, side-effect-free alternative to conventional antifungals for managing VVC, especially in cases where drugs fail or cause issues.
Read More
Probiotics enhance yeast infection treatmentRole of Probiotic in Vulvovaginal Candidiasis: A Randomised Controlled Non-blinded Trial from India.
We aimed to understand if adding probiotics to standard antifungal treatment improves outcomes for vulvovaginal candidiasis (VVC). In our study, 60 women diagnosed with VVC were divided into two groups.
One group received just antifungal medication, while the other received both antifungal and probiotic treatments.
Results indicated that those who took probiotics alongside their antifungal showed better improvement and had lower relapse rates. This suggests that probiotics can be a beneficial addition to standard yeast infection treatments.
Read More
Lactic acid bacteria inhibit Candida albicansInhibiting pathogenicity of vaginal Candida albicans by lactic acid bacteria and MS analysis of their extracellular compounds.
We explored how lactic acid bacteria (LAB) can combat the harmful effects of Candida albicans, the fungus responsible for yeast infections. Through our study, we found that the supernatant from LAB like Lactobacillus crispatus and L. gasseri effectively inhibited the growth and harmful activity of C. albicans.
Specifically, L. gasseri showed exceptional ability in preventing the formation of biofilms and hyphae, crucial stages in fungal development. Additionally, the metabolites produced by these bacteria downregulated key genes associated with C. albicans, reinforcing their role in maintaining vaginal health.
Overall, while the findings are promising, further research is needed to confirm the clinical effectiveness of these metabolites in treating or preventing yeast infections.
Read More